Lupin Limited launched Formoflo-G® MDI, a fixed-dose triple-combination metered-dose inhaler (MDI) for the management of chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI). The company describes the launch as a significant development in respiratory care, offering an additional treatment option for eligible patients living with COPD.
Triple-Combination Inhaler for COPD Treatment
Formoflo-G® MDI combines three active ingredients: Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate. According to Lupin, the inhaler is intended for the long-term management of moderate to severe COPD. The product offers a fixed-dose combination in a single inhaler, administered twice daily. By bringing together three established therapies, it adds another option for healthcare professionals managing patients who require this combination. COPD remains a major public health concern in India, affecting millions of people and contributing significantly to respiratory illness, disability and premature deaths.
Lupin Highlights Commitment to Respiratory Care
Nilesh Gupta, Managing Director, Lupin, said, “As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G® MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases.”
New Addition to Lupin’s Respiratory Portfolio
Rajeev Sibal, President – India Region Formulations, Lupin, said, “Formoflo-G® MDI marks an important addition to our respiratory portfolio, bringing together three established therapies in a single inhaler. It strengthens Lupin’s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients. It reflects our commitment to delivering innovative, high-quality therapies that help improve patient outcomes.” As per the press release, with this launch, Lupin further strengthens its respiratory care portfolio in India. The introduction of Formoflo-G® MDI also reflects the pharmaceutical industry’s ongoing efforts to expand treatment options for chronic respiratory conditions through combination therapies.